Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:03 PM
Ignite Modification Date:
2025-12-24 @ 4:03 PM
NCT ID:
NCT02343666
Eligibility Criteria:
Inclusion Criteria:
* HIV-1 seropositive
* Stable, continuous antiretroviral treatment, defined as a multi-drug regimen (excluding zidovudine, also known as azidothymidine \[AZT\], Retrovir) prior to enrollment, as demonstrated by HIV plasma viral load \< 50 copies/mL
* Previously untreated non-Hodgkin lymphoma or Hodgkin lymphoma; all stages of disease are allowed; also eligible are patients who have started or completed one or more cycles of treatment as part of a planned first line regimen, or those who have received local radiation or surgery or corticosteroids for disease control
* Planned treatment with standard first line therapy for non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)
* Karnofsky performance score \>= 70%
* Subjects must agree to use effective means to prevent conception from enrollment through completion of the study
* Female subjects: if of child bearing potential, must have negative serum or urine pregnancy test within 7 days of enrollment
* Subjects must be on a prophylactic regimen for Pneumocystis jiroveci pneumonia, or agree to begin such treatment, if CD4+ cell counts are observed to be =\< 200/ul in peripheral blood
* Able to understand, and the willingness to give, informed consent for the study
Exclusion Criteria:
* Central nervous system (CNS) lymphoma: CNS involvement by lymphoma, including parenchymal brain or spinal cord lymphoma or known presence of leptomeningeal disease prior to registration
* Patients with renal, hepatic, pulmonary, or cardiac disease that exclude delivery of standard chemotherapy
* Active (uncontrolled) infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents (excluding HIV)
* Hepatitis B surface antigen positive
* Hepatitis C virus (HCV) antibody positive and detectable HCV quantitative ribonucleic acid (RNA), with clinical evidence of cirrhosis as determined by the principal investigator
* Requiring active treatment for Toxoplasma gondii infection
* Malignancy other than lymphoma, unless (1) in complete remission and more than 5 years from last treatment, or (2) cervical/anal squamous cell carcinoma in situ or (3) superficial basal cell and squamous cell cancers of the skin
* History of HIV-associated encephalopathy; dementia of any kind; seizures in the past 12 months
* Any perceived inability to directly provide informed consent (note: consent may not be obtained by means of a legal guardian)
* Any concurrent or past medical condition that, in the opinion of the investigator, would exclude the subject from participation
* Patients who have received a vaccine for HIV-1 or any prior gene modified cell product, at any time
* A medical history of noncompliance with HAART or medical therapy
* Pregnant women or nursing mothers
* Use of zidovudine as part of the HAART regimen (a drug substitution for zidovudine at the time of study entry is allowed)
* Known hypersensitivity to any of the products used in the trial - G-CSF (Neupogen, filgrastim), plerixafor (Mozobil), or any components of the chemotherapeutic agents or O6BG/BCNU in vivo selection regimens
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
66 Years
Study:
NCT02343666
Study Brief:
Protocol Section:
NCT02343666